Huons Global Co., Ltd. (084110.KQ)
KRW 46950.0
(-1.68%)
KRW 46950.0
(-1.68%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 122.92 Billion KRW | 32.9% |
| 2022 | 85.95 Billion KRW | 13.76% |
| 2021 | 75.55 Billion KRW | -14.5% |
| 2020 | 88.37 Billion KRW | 21.22% |
| 2019 | 72.9 Billion KRW | 7.22% |
| 2018 | 67.99 Billion KRW | 10.04% |
| 2017 | 61.79 Billion KRW | 113.84% |
| 2016 | 28.89 Billion KRW | 146.49% |
| 2015 | 11.72 Billion KRW | -61.05% |
| 2014 | 30.09 Billion KRW | 7.75% |
| 2013 | 27.93 Billion KRW | 89.2% |
| 2012 | 14.76 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 30.32 Billion KRW | 17.71% |
| 2024 Q1 | 25.81 Billion KRW | 30.27% |
| 2023 FY | 114.23 Billion KRW | 32.9% |
| 2023 Q1 | 24.46 Billion KRW | -11.87% |
| 2023 Q4 | 19.81 Billion KRW | -37.36% |
| 2023 Q2 | 36.4 Billion KRW | 48.85% |
| 2023 Q3 | 31.64 Billion KRW | -13.1% |
| 2022 Q4 | 27.75 Billion KRW | 46.5% |
| 2022 Q1 | 20.67 Billion KRW | 29.19% |
| 2022 FY | 85.95 Billion KRW | 13.76% |
| 2022 Q2 | 20.43 Billion KRW | -1.18% |
| 2022 Q3 | 18.94 Billion KRW | -7.27% |
| 2021 Q1 | 20.32 Billion KRW | -16.51% |
| 2021 Q2 | 19.12 Billion KRW | -5.89% |
| 2021 Q3 | 19.14 Billion KRW | 0.11% |
| 2021 Q4 | 16 Billion KRW | -16.42% |
| 2021 FY | 75.55 Billion KRW | -14.5% |
| 2020 Q2 | 21.8 Billion KRW | 15.34% |
| 2020 Q3 | 24.2 Billion KRW | 11.03% |
| 2020 Q4 | 24.34 Billion KRW | 0.57% |
| 2020 Q1 | 18.9 Billion KRW | -5.2% |
| 2020 FY | 88.37 Billion KRW | 21.22% |
| 2019 Q4 | 19.93 Billion KRW | -3.85% |
| 2019 Q3 | 20.73 Billion KRW | 43.23% |
| 2019 Q2 | 14.47 Billion KRW | -18.47% |
| 2019 Q1 | 17.75 Billion KRW | 54.45% |
| 2019 FY | 72.9 Billion KRW | 7.22% |
| 2018 FY | 67.99 Billion KRW | 10.04% |
| 2018 Q4 | 11.49 Billion KRW | -46.86% |
| 2018 Q3 | 21.63 Billion KRW | 20.7% |
| 2018 Q2 | 17.92 Billion KRW | 5.8% |
| 2018 Q1 | 16.94 Billion KRW | 3.31% |
| 2017 Q4 | 16.39 Billion KRW | -10.77% |
| 2017 Q1 | 11.38 Billion KRW | -4.17% |
| 2017 Q2 | 15.63 Billion KRW | 37.3% |
| 2017 Q3 | 18.37 Billion KRW | 17.57% |
| 2017 FY | 61.79 Billion KRW | 113.84% |
| 2016 Q2 | 4.18 Billion KRW | 12.83% |
| 2016 Q4 | 11.87 Billion KRW | 30.16% |
| 2016 Q3 | 9.12 Billion KRW | 118.18% |
| 2016 Q1 | 3.7 Billion KRW | 55.85% |
| 2016 FY | 28.89 Billion KRW | 146.49% |
| 2015 Q2 | 3.04 Billion KRW | 68.45% |
| 2015 Q4 | 2.37 Billion KRW | -46.95% |
| 2015 Q3 | 4.48 Billion KRW | 47.04% |
| 2015 FY | 11.72 Billion KRW | -61.05% |
| 2015 Q1 | 1.81 Billion KRW | -74.2% |
| 2014 Q3 | 8.41 Billion KRW | 7.05% |
| 2014 Q1 | 6.8 Billion KRW | 1.1% |
| 2014 Q2 | 7.85 Billion KRW | 15.46% |
| 2014 Q4 | 7.01 Billion KRW | -16.6% |
| 2014 FY | 30.09 Billion KRW | 7.75% |
| 2013 Q2 | 7.44 Billion KRW | 34.52% |
| 2013 FY | 27.93 Billion KRW | 89.2% |
| 2013 Q1 | 5.53 Billion KRW | 74.43% |
| 2013 Q3 | 8.21 Billion KRW | 10.32% |
| 2013 Q4 | 6.73 Billion KRW | -18.06% |
| 2012 FY | 14.76 Billion KRW | 0.0% |
| 2012 Q4 | 3.17 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.54 Billion KRW | 729.02% |
| CMG Pharmaceutical Co., Ltd. | 5.72 Billion KRW | -2047.074% |
| Celltrion Pharm, Inc. | 36.07 Billion KRW | -240.787% |
| DongKook Pharmaceutical Co., Ltd. | 66.87 Billion KRW | -83.817% |
| Enzychem Lifesciences Corporation | -14.35 Billion KRW | 956.248% |
| Humedix Co., Ltd. | 37.31 Billion KRW | -229.467% |
| Boditech Med Inc. | 33.44 Billion KRW | -267.563% |
| EuBiologics Co., Ltd. | 7.69 Billion KRW | -1496.603% |
| FutureChem Co.,Ltd | -8.4 Billion KRW | 1562.009% |
| Huons Co., Ltd. | 59.79 Billion KRW | -105.578% |
| BNC Korea Co., Ltd. | 10.81 Billion KRW | -1036.221% |
| AptaBio Therapeutics Inc. | -16.37 Billion KRW | 850.749% |